Compare DSWL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | ALXO |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 79.7M |
| IPO Year | 1995 | 2020 |
| Metric | DSWL | ALXO |
|---|---|---|
| Price | $3.54 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 16.2K | ★ 279.7K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | ★ 5.59% | N/A |
| EPS Growth | ★ 20.23 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $65,664,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.93 | $0.40 |
| 52 Week High | $4.48 | $2.27 |
| Indicator | DSWL | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 50.89 |
| Support Level | $3.53 | $1.29 |
| Resistance Level | $3.60 | $1.56 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 9.43 | 51.09 |
Deswell Industries Inc is engaged in the manufacturing and selling of injection-molded plastic parts and components. In addition, it also offers manufacturing services for electronic products and subassemblies and manufactures metallic molds and accessory parts for original equipment manufacturers and contract manufacturers. The company conducts all of its manufacturing activities at separate plastics, electronics and metallic operation factories located in the People's Republic of China. It operates through the Plastic Injection Molding and Electronic Products Assembling segments. The firm offers products such as automobile components, medical testing equipment, parts for audio equipment, av receivers, active subwoofers, digital system key sets, communication products and others.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.